State-of-the-Art Drug Discovery and Development in Poland (2nd Edition)
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 15 September 2024 | Viewed by 90
Special Issue Editor
Interests: combination chemotherapy; drug delivery; targeted therapy; cancer biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the last few decades, we have observed a significant shift in drug design and development methods. Two distinct technological trends are involved in this change. One represents advances made in exploring areas such as genomic sequencing, protein science, and structural biology. New technologies provide vast numbers of data, uncover a wide range of potential drug targets, and facilitate more accurate target identification and validation. The second trend involves the empowerment of computational scientists to utilize these massive databases thanks to the significant number of tools and software packages available for analyzing and interpreting biological complexity. Technological advances in various areas of omics have allowed the exploration of different approaches to improve the success of drug design and development.
All authors who are actively involved in drug discovery and development in Poland are invited to contribute to this Special Issue. Original research articles and reviews on the hottest topics related to identifying and introducing new medicines and cutting-edge methodological advances are welcome.
Possible research topics include, but are not limited to, the following:
- In silico drug target profiling;
- Drug delivery systems;
- Drug–drug interactions;
- Target-based screening;
- Phenotypic screening;
- Pharmaceutical modeling;
- Computational chemistry;
- Targeted therapy;
- Biomarkers;
- Bioimaging.
Dr. Aleksandra Romaniuk-Drapała
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- in silico drug target profiling
- drug delivery systems
- drug–drug interactions
- target-based screening
- phenotypic screening
- pharmaceutical modeling
- computational chemistry
- targeted therapy
- biomarkers
- bioimaging
